Trials / Withdrawn
WithdrawnNCT00704951
Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections in Immuncompromised Patients in Austria (Study P05532)(WITHDRAWN)
P05532 Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections (IFIs) in Immuncompromised Patients in Austria. Version 1, 08-Nov-2007.
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this program is to determine the frequency of the use of Posaconazole in immunocompromised patients refractory to first line therapy receiving therapeutic treatment based on different pathogens in comparison to other antifungal therapy. A further objective is to determine the frequency of the use of Posaconazole in immunocompromised patients receiving prophylactic treatment in comparison to other antifungal prophylaxis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Posaconazole or alternative fungal treatment | Dosage of Posaconazole: Prophylactic dosing: 200mg tid (600mg/day) Treatment dosing: 400mg bid (800mg/day) |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2011-05-01
- Completion
- 2011-06-01
- First posted
- 2008-06-25
- Last updated
- 2015-08-25
Source: ClinicalTrials.gov record NCT00704951. Inclusion in this directory is not an endorsement.